BACKGROUND: Our genome-wide association study (GWAS) of chronic lymphocytic leukemia (CLL) identified 4 highly correlated intronic variants within the IRF8 gene that were associated with CLL. These results were further supported by a recent meta-analysis of our GWAS with two other GWAS of CLL, supporting the IRF8 gene as a strong candidate for CLL risk. METHODS: To refine the genetic association of CLL risk, we conducted Sanger sequencing of IRF8 in 94 CLL cases and 96 controls. We then conducted fine mapping by genotyping 39 variants (of which 10 were identified from sequencing) in 745 CLL cases and 1,521 controls. We also assessed these associations with risk of other non-Hodgkin lymphoma (NHL) subtypes. RESULTS: The strongest association with CLL risk was observed with a common single-nucleotide polymorphism (SNP) located within the 3' untranslated region (UTR) of IRF8 (rs1044873, log additive OR = 0.7, P = 1.81 × 10(-6)). This SNP was not associated with the other NHL subtypes (all P > 0.05). CONCLUSIONS: We provide evidence that rs1044873 in the IRF8 gene accounts for the initial GWAS signal for CLL risk. This association appears to be unique to CLL with little support for association with other common NHL subtypes. Future work is needed to assess functional role of IRF8 in CLL etiology. IMPACT: These data provide support that a functional variant within the 3'UTR of IRF8 may be driving the GWAS signal seen on 16q24.1 for CLL risk.
BACKGROUND: Our genome-wide association study (GWAS) of chronic lymphocytic leukemia (CLL) identified 4 highly correlated intronic variants within the IRF8 gene that were associated with CLL. These results were further supported by a recent meta-analysis of our GWAS with two other GWAS of CLL, supporting the IRF8 gene as a strong candidate for CLL risk. METHODS: To refine the genetic association of CLL risk, we conducted Sanger sequencing of IRF8 in 94 CLL cases and 96 controls. We then conducted fine mapping by genotyping 39 variants (of which 10 were identified from sequencing) in 745 CLL cases and 1,521 controls. We also assessed these associations with risk of other non-Hodgkin lymphoma (NHL) subtypes. RESULTS: The strongest association with CLL risk was observed with a common single-nucleotide polymorphism (SNP) located within the 3' untranslated region (UTR) of IRF8 (rs1044873, log additive OR = 0.7, P = 1.81 × 10(-6)). This SNP was not associated with the other NHL subtypes (all P > 0.05). CONCLUSIONS: We provide evidence that rs1044873 in the IRF8 gene accounts for the initial GWAS signal for CLL risk. This association appears to be unique to CLL with little support for association with other common NHL subtypes. Future work is needed to assess functional role of IRF8 in CLL etiology. IMPACT: These data provide support that a functional variant within the 3'UTR of IRF8 may be driving the GWAS signal seen on 16q24.1 for CLL risk.
Authors: Christopher S Carlson; Michael A Eberle; Mark J Rieder; Qian Yi; Leonid Kruglyak; Deborah A Nickerson Journal: Am J Hum Genet Date: 2003-12-15 Impact factor: 11.025
Authors: Susan L Slager; Kari G Rabe; Sara J Achenbach; Celine M Vachon; Lynn R Goldin; Sara S Strom; Mark C Lanasa; Logan G Spector; Laura Z Rassenti; Jose F Leis; Nicola J Camp; Martha Glenn; Neil E Kay; Julie M Cunningham; Curtis A Hanson; Gerald E Marti; J Brice Weinberg; Vicki A Morrison; Brian K Link; Timothy G Call; Neil E Caporaso; James R Cerhan Journal: Blood Date: 2010-12-03 Impact factor: 22.113
Authors: Adam Siepel; Gill Bejerano; Jakob S Pedersen; Angie S Hinrichs; Minmei Hou; Kate Rosenbloom; Hiram Clawson; John Spieth; Ladeana W Hillier; Stephen Richards; George M Weinstock; Richard K Wilson; Richard A Gibbs; W James Kent; Webb Miller; David Haussler Journal: Genome Res Date: 2005-07-15 Impact factor: 9.043
Authors: Tony Kwan; David Benovoy; Christel Dias; Scott Gurd; Cathy Provencher; Patrick Beaulieu; Thomas J Hudson; Rob Sladek; Jacek Majewski Journal: Nat Genet Date: 2008-01-13 Impact factor: 38.330
Authors: Chang Hoon Lee; Mark Melchers; Hongsheng Wang; Ted A Torrey; Rebecca Slota; Chen-Feng Qi; Ji Young Kim; Patricia Lugar; Hee Jeong Kong; Lila Farrington; Boris van der Zouwen; Jeff X Zhou; Vassilios Lougaris; Peter E Lipsky; Amrie C Grammer; Herbert C Morse Journal: J Exp Med Date: 2005-12-27 Impact factor: 14.307
Authors: Huihuang Yan; Shulan Tian; Geffen Kleinstern; Zhiquan Wang; Jeong-Heon Lee; Nicholas J Boddicker; James R Cerhan; Neil E Kay; Esteban Braggio; Susan L Slager Journal: Hum Mol Genet Date: 2020-09-29 Impact factor: 6.150
Authors: Jean L Koff; Dai Chihara; Anh Phan; Loretta J Nastoupil; Jessica N Williams; Christopher R Flowers Journal: Curr Hematol Malig Rep Date: 2015-09 Impact factor: 3.952
Authors: Zhijun Qiu; Kenneth N Holder; An-Ping Lin; Jamie Myers; Shoulei Jiang; Karla M Gorena; Marsha C Kinney; Ricardo C T Aguiar Journal: Cancer Genet Date: 2020-06-03
Authors: Geffen Kleinstern; Nicola J Camp; Lynn R Goldin; Celine M Vachon; Claire M Vajdic; Silvia de Sanjose; J Brice Weinberg; Yolanda Benavente; Delphine Casabonne; Mark Liebow; Alexandra Nieters; Henrik Hjalgrim; Mads Melbye; Bengt Glimelius; Hans-Olov Adami; Paolo Boffetta; Paul Brennan; Marc Maynadie; James McKay; Pier Luigi Cocco; Tait D Shanafelt; Timothy G Call; Aaron D Norman; Curtis Hanson; Dennis Robinson; Kari G Chaffee; Angela R Brooks-Wilson; Alain Monnereau; Jacqueline Clavel; Martha Glenn; Karen Curtin; Lucia Conde; Paige M Bracci; Lindsay M Morton; Wendy Cozen; Richard K Severson; Stephen J Chanock; John J Spinelli; James B Johnston; Nathaniel Rothman; Christine F Skibola; Jose F Leis; Neil E Kay; Karin E Smedby; Sonja I Berndt; James R Cerhan; Neil Caporaso; Susan L Slager Journal: Blood Date: 2018-04-19 Impact factor: 25.476